Domenica Lorusso, MD, PhD, on Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer

November 03, 2026

Domenica Lorusso, MD, PhD, of Humanitas University, summarizes findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 study, which showed sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate, provided statistically significant and clinically meaningful improvements in progression-free and overall survival and response vs treatment of physician’s choice in patients with previously treated advanced or recurrent endometrial cancer, with manageable safety (Abstract LBA11). 

Related Content